Search | Page 17 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission (QUAZAR AML-001)

    ... Associated Drug(s):  Azacitidine Phase:  ... Intervention:  Drug: 300 mg Oral Azacitidine Maintenance therapy Drug: Placebo ...

    Clinical Trial last updated 04/29/2016 - 8:39am.

  2. CC-486 (Oral Azacitidine) Bioequivalence Study in Patients With Solid Tumor or Hematologic Malignancies

    ... Associated Drug(s):  Azacitidine Phase:  ... every 4 weeks for ≤ 6 (four-week) cycles Other Names: Azacitidine for Injection AZA ...

    Clinical Trial last updated 04/28/2016 - 10:47am.

  3. MDS Drug Therapy

    ... (FDA) has approved three medicines to treat MDS: Azacitidine (Vidaza®) for both low- and high-risk patients with all ... Azacitidine (Vidaza®) Azacitidine ...

    Topic section last updated 03/10/2016 - 11:26pm.

  4. AC220 With 5-Aza or Low Dose Cytarabine

    ... of AC220 (quizartinib) that can be given with either 5- azacitidine (azacitidine) or cytarabine to patients with AML or MDS. The goal of the ...

    Clinical Trial last updated 05/03/2016 - 11:11am.

  5. New therapeutics for myelodysplastic syndromes

    ... lenalidomide (Revlimidâ) and the azanucleosides, azacitidine (Vidazaâ) and decitabine (Dacogenâ).  Although these ... Targeting the MDS clone:   The azanucleosides (azacitidine and decitabine) remain the best treatment option for many ...

    Research Review last updated 05/02/2016 - 9:28am.

  6. Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDS

    ... Phase II trial combining azacitidine with valproic acid as maintenance therapy post allogeneic stem ... MDS/AML. We hypothesize that adding valproic acid to azacitidine will improve outcomes via both direct anti-tumor and ... is near 40%. We hypothesize that valproic acid and azacitidine will prolong survival, with a 1 year survival goal of 60%. In ...

    Clinical Trial last updated 04/29/2016 - 12:35pm.

  7. More is better: Combination therapies for myelodysplastic syndromes

    ... FDA-approved medications for MDS: lenalidomide , azacitidine , and decitabine .  Although these agents can be ... therapy is using an epigenetic approach, where one combines azacitidine or decitabine (the class of drugs known as hypomethylating agents) ...

    Research Review last updated 05/02/2016 - 9:14am.

  8. A Safety and Pharmacology Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) Administered Alone or in Combination With Azacitidine in Patients With Myelodysplastic Syndromes

    ... populations, including treatment in combination with azacitidine . Status:  ... Associated Drug(s):  Azacitidine Phase:  ...

    Clinical Trial last updated 04/27/2016 - 9:57am.

  9. Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)

    ... Opdivo (nivolumab), alone or in combination with Vidaza ( azacitidine ), can help to control MDS. The safety of these drug ... Associated Drug(s):  Azacitidine Phase:  ...

    Clinical Trial last updated 04/29/2016 - 11:16am.

  10. Recent developments in myelodysplastic syndromes

    ... were approved for MDS between the years 2004 – 2006 ( azacitidine , decitabine , and lenalidomide ), none of these ... or molecular markers have consistently predicted response to azacitidine or decitabine.  -There are several novel agents and combinations ...

    Research Review last updated 05/02/2016 - 9:16am.